Eliem Therapeutics, Inc. (ELYM)
NASDAQ: ELYM · IEX Real-Time Price · USD
2.750
-0.020 (-0.72%)
Mar 28, 2024, 3:58 PM EDT - Market closed

Eliem Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2022202120202019
Selling, General & Admin
18.9212.352.430.68
Research & Development
26.2123.329.344.02
Other Operating Expenses
009.162.75
Operating Expenses
45.1435.6720.937.45
Operating Income
-45.14-35.67-20.93-7.45
Other Expense / Income
0.1111.81-0.26-0.9
Pretax Income
-45.24-47.48-20.67-6.55
Net Income
-45.24-47.48-20.67-6.55
Preferred Dividends
04.552.290.84
Net Income Common
-45.24-52.03-22.95-7.39
Shares Outstanding (Basic)
261222
Shares Outstanding (Diluted)
261222
Shares Change
114.60%460.40%31.72%-
EPS (Basic)
-1.72-4.24-10.49-4.45
EPS (Diluted)
-1.72-4.24-10.49-4.45
Free Cash Flow
-37.37-36.07-14.1-5.01
Free Cash Flow Per Share
-1.42-2.94-6.44-3.02
EBITDA
-44.8-47.48-20.67-6.55
Depreciation & Amortization
0.44000
EBIT
-45.24-47.48-20.67-6.55
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).